OverviewChartNewsTraderScreen

DE000HG8Y0Q6/  DE000HG8Y0Q6  /

Frankfurt Zertifikate
2024-06-11  11:20:52 AM Chg.-0.230 Bid11:22:10 AM Ask11:22:10 AM Underlying Strike price Expiration date Option type
12.520EUR -1.80% 12.520
Bid Size: 10,000		 12.620
Ask Size: 10,000		 Novo Nordisk 75.7212 USD 2078-12-31 Call
GlobeNewswire 06-10 RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships
GlobeNewswire 06-10 Veru to Present at the American Diabetes Association's 84th Scientific Sessions
GlobeNewswire 06-03 Aeterna Zentaris and Ceapro Complete Merger Transaction
GlobeNewswire 06-03 Aeterna Zentaris and Ceapro Complete Merger Transaction
GlobeNewswire 05-31 Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia...
GlobeNewswire 05-30 Anaqua Annual User Experience Conference to Feature Keynotes from Microsoft, SAP, USPTO, and More
GlobeNewswire 05-22 Veru to Present at the Jefferies Global Healthcare Conference
GlobeNewswire 05-15 Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Cl...
GlobeNewswire 05-15 Aeterna Zentaris Reports First Quarter 2024 Financial Results
GlobeNewswire 05-14 Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Sci...
GlobeNewswire 05-09 US Neurologists Report Route of Administration as a Critical Factor when Evaluating Future Parkinson...
GlobeNewswire 05-07 Vect-Horus to Take Part in a Roundtable Discussion at Viva Technology Conference
TeleTrader 04-25 Europe opens mostly down after corporate earnings
GlobeNewswire 04-22 Vect-Horus Publication in Pharmaceutics Outlines How Vectors Can Improve Delivery of Therapeutics to...
GlobeNewswire 04-22 SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into cli...
GlobeNewswire 04-22 SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into cli...
GlobeNewswire 04-11 Robbins LLP is Investigating the Acquisition of Catalent, Inc. (CTLT) by Novo Holdings
GlobeNewswire 04-02 Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting C...
GlobeNewswire 04-02 Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
GlobeNewswire 03-28 Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategi...
GlobeNewswire 03-27 Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completio...
GlobeNewswire 03-25 Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the ...
GlobeNewswire 03-18 Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ ...
GlobeNewswire 03-15 American Kidney Fund Announces 2024 Class of Corporate Members Providing Support in the Fight Agains...
GlobeNewswire 03-15 University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated...